Noah Nasser profile page

Noah Nasser is CEO of datma, a leading provider of federated Real-World Data platforms and related analytical tools. With more than 25 years of experience in biotechnology, Noah brings a broad background in the development and commercialization of novel technology to advance human health, including most recently serving as the CEO of Serimmune. Previously, he held the role of Chief Commercial Officer at Human Longevity, Inc., a direct-to-consumer health screening organization combining proprietary imaging and genetic technologies. Prior to Human Longevity, Noah was chief commercial officer at Counsyl, a market-leading genetic testing laboratory focused on women's health applications, including non-invasive prenatal testing, expanded carrier screening and hereditary cancer screening. Noah led Counsyl's commercial team through its acquisition in 2018 by Myriad Genetics, Inc. He previously held senior leadership positions at San Diego-based biotechnology company AltheaDx, and San Carlos-based Verinata Health, a leader in non-invasive prenatal testing (NIPT), where he led his team through the company's 2013 acquisition by Illumina.